JPWO2021067335A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021067335A5
JPWO2021067335A5 JP2022520290A JP2022520290A JPWO2021067335A5 JP WO2021067335 A5 JPWO2021067335 A5 JP WO2021067335A5 JP 2022520290 A JP2022520290 A JP 2022520290A JP 2022520290 A JP2022520290 A JP 2022520290A JP WO2021067335 A5 JPWO2021067335 A5 JP WO2021067335A5
Authority
JP
Japan
Prior art keywords
chemical formula
pharmaceutically acceptable
following chemical
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551583A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053369 external-priority patent/WO2021067335A1/en
Publication of JP2022551583A publication Critical patent/JP2022551583A/ja
Publication of JPWO2021067335A5 publication Critical patent/JPWO2021067335A5/ja
Pending legal-status Critical Current

Links

JP2022520290A 2019-10-01 2020-09-30 Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物 Pending JP2022551583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909006P 2019-10-01 2019-10-01
US62/909,006 2019-10-01
PCT/US2020/053369 WO2021067335A1 (en) 2019-10-01 2020-09-30 Benzoxazinone compounds as klk5/7 dual inhibitors

Publications (2)

Publication Number Publication Date
JP2022551583A JP2022551583A (ja) 2022-12-12
JPWO2021067335A5 true JPWO2021067335A5 (zh) 2023-09-29

Family

ID=75274622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520290A Pending JP2022551583A (ja) 2019-10-01 2020-09-30 Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物

Country Status (12)

Country Link
US (2) US11643420B2 (zh)
EP (1) EP4037687A4 (zh)
JP (1) JP2022551583A (zh)
KR (1) KR20220091488A (zh)
CN (1) CN114615984A (zh)
AU (1) AU2020359526A1 (zh)
BR (1) BR112022005881A2 (zh)
CA (1) CA3151626A1 (zh)
IL (1) IL291398A (zh)
MX (1) MX2022003929A (zh)
TW (1) TW202126631A (zh)
WO (1) WO2021067335A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1309556C (en) 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2224381A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
NZ506985A (en) 1998-03-31 2003-10-31 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2525383C (en) 2003-06-06 2012-03-06 Arexis Ab Use of heterocyclic compounds as scce inhibitors
SI3097085T1 (sl) * 2014-01-23 2020-11-30 Sixera Pharma Ab Derivati benzoksazinona za zdravljenje kožnih bolezni

Similar Documents

Publication Publication Date Title
RU2606947C2 (ru) Борсодержащие малые молекулы
JP5389668B2 (ja) 皮膚浸透率の非常に高い１Ｈ−イミダゾ［４，５−ｃ］キノリン−４−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
TWI689490B (zh) 用於治療纖維化之經取代之芳族化合物及相關方法
JP2007530523A5 (zh)
JP2001506267A (ja) アミノステロールエステル化合物
JP2002539243A (ja) 受精能を向上させるための組成物
JP2015519358A (ja) スルフォラファンの単離及び精製
JP2001525803A (ja) 勃起機能不全治療用の薬剤の調製のためのミソプロストール及び／又はミソプロストール酸の用途
JP2003515580A (ja) （ｓ）−２−エトキシ−３−〔４−（２−［４−メタンスルホニルオキシフェニル］エトキシ）フェニル〕プロパン酸の微粉砕形
JPH0827081A (ja) Ｌ−カルニチン塩および化粧用および皮膚病処置用医薬組成物
JP2562475B2 (ja) 新規化合物、医療組成物、及び炎症及び痛みの治療方法
JP2003516327A (ja) アテローム性動脈硬化の予防および／または治療方法
CN108341752A (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
JPH08109131A (ja) Ｈｉｖプロテアーゼ抑制因子組成物
US20230046317A1 (en) Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
CN113101289A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
US20180085345A1 (en) Methods of tracking skin conditions using cyclolignan compounds
JPWO2021067335A5 (zh)
EP3435990B1 (en) Stable pharmaceutical compositions for topical administration and uses thereof
JPH10513186A (ja) Ｈｉｖプロテアーゼ阻害剤インジナビル及び逆転写酵素阻害剤３ｔｃを必要に応じてａｚｔ、ｄｄｉ、又はｄｄｃと共に用いるｈｉｖ感染の組合せ治療
CN115925640A (zh) ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯及其制备方法和应用
TW201811307A (zh) 2-(2-乙氧基-2-氧代乙基)(甲基)胺基-2-氧代乙基5-(十四烷氧基)呋喃-2-羧酸酯之皮膚調配物
JP2003512425A (ja) ６−メトキシ−２−ナフチル酢酸プロドラッグ
RU2004102398A (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости